AN2 Therapeutics, Inc. Net Fee Amt
AN2 Therapeutics, Inc. (ANTX) had Net Fee Amt of $964.97 as of 2026-09-14, per its S-8 filed 2026-09-14.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-09-14
- 2026-09-14: Net Fee Amt $964.97.
- 2026-04-09: Net Fee Amt $18.69K.
| Period end | Net Fee Amt |
|---|---|
| 2026-09-14 | $964.97 S-8 · filed 2026-09-14 |
| 2026-04-09 | $18.69K S-3 · filed 2026-04-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |